A new once-monthly injectable form of olanzapine, one of the most effective antipsychotics available, could soon reach the market without the burdensome three-hour monitoring window that has kept the existing injectable version largely sidelined. TEV-749, developed by Teva Pharmaceuticals in partnership with MedIncell, is a subcutaneous olanzapine injection that delivered significant symptom improvement in Phase 3 trials and, critically, produced zero cases of the dangerous sedation syndrome that has plagued the only other long-acting olanzapine injection for years. The FDA accepted Teva’s New Drug Application on February 20, 2026, and the drug is now under review.
For families managing a loved one’s schizophrenia or psychotic symptoms related to dementia, the practical implications are substantial. Instead of daily pills that can be forgotten, refused, or inconsistently absorbed, a single monthly shot administered in a clinic could maintain steady medication levels. This article covers what TEV-749 actually is and how it works, the clinical trial results that got it to the FDA’s door, how it compares to existing long-acting injectable antipsychotics, the side effects families should know about, and what this could mean for real-world patient care.
Table of Contents
- What Is This New Once-Monthly Injectable Antipsychotic and How Does It Work?
- What Did the Clinical Trials Actually Show?
- How TEV-749 Compares to Other Long-Acting Injectable Antipsychotics
- Side Effects and Safety Data Families Should Understand
- The Post-Injection Monitoring Problem TEV-749 Could Solve
- What This Means for Medication Adherence
- What Happens Next and When Could TEV-749 Be Available?
- Conclusion
- Frequently Asked Questions
What Is This New Once-Monthly Injectable Antipsychotic and How Does It Work?
TEV-749 is an extended-release injectable suspension of olanzapine, a second-generation antipsychotic that has been used in pill form for decades. What makes this formulation different is MedIncell’s proprietary copolymer technology, which encapsulates the olanzapine and releases it slowly and steadily after a single subcutaneous injection. Unlike intramuscular shots that deposit medication deep in muscle tissue, subcutaneous injections go just under the skin, which is generally less painful and can be administered more quickly. The reason this matters is context. Olanzapine already has a long-acting injectable form called Zyprexa Relhypv, but that product comes with a serious catch.
It carries a risk of post-injection delirium/sedation syndrome, or PDSS, a condition where the drug floods the bloodstream too quickly and causes extreme drowsiness, confusion, or even loss of consciousness. Because of that risk, the FDA requires Zyprexa Relhypv to be administered only in certified healthcare facilities, and patients must be monitored for three hours after every single injection. For a monthly medication, that means three hours in a clinical setting twelve times a year, which is why many clinicians simply do not prescribe it despite olanzapine’s proven effectiveness. TEV-749’s subcutaneous delivery and controlled-release mechanism appear to sidestep this problem entirely. In the Phase 3 SOLARIS trial, which tracked participants for up to 56 weeks, there were zero observed cases of PDSS. If the FDA approves TEV-749, it would become the first long-acting injectable olanzapine that does not require post-injection monitoring, making outpatient administration genuinely feasible.
What Did the Clinical Trials Actually Show?
The Phase 3 SOLARIS trial was the pivotal study behind Teva’s FDA submission. The trial met its primary endpoint, showing a statistically significant improvement in PANSS total scores from baseline to Week 8 compared to placebo. The PANSS, or Positive and Negative Syndrome Scale, is the standard tool psychiatrists use to measure the severity of schizophrenia symptoms, including hallucinations, delusions, disorganized thinking, and social withdrawal. Beyond the primary measure, TEV-749 also improved scores on the CGI-S, which rates overall illness severity as judged by the clinician, and the PSP, which evaluates how well a patient functions in daily life, relationships, and self-care. However, families should understand what these results do and do not tell us.
The SOLARIS trial was conducted in adults with schizophrenia, not in elderly patients with dementia-related psychosis. Antipsychotics as a class carry an FDA black box warning about increased mortality risk in elderly patients with dementia-related psychosis, and there is no reason to expect TEV-749 would be exempt from that warning. If your loved one has dementia with psychotic features, any antipsychotic use should involve a careful risk-benefit conversation with their physician. The trial data is promising for schizophrenia, but extrapolating those results to other populations requires caution. Patient and healthcare professional satisfaction surveys collected during the SOLARIS trial were positive, which is worth noting because adherence to antipsychotic regimens is one of the biggest challenges in real-world treatment. A medication that patients are willing to continue taking is, in practical terms, more effective than a superior drug that gets abandoned.
How TEV-749 Compares to Other Long-Acting Injectable Antipsychotics
TEV-749 would not be the first monthly injectable antipsychotic on the market. Several already exist, and understanding the landscape helps put this development in perspective. Invega Sustenna delivers paliperidone palmitate via monthly intramuscular injection and has been a workhorse in schizophrenia treatment for years. Abilify Maintena provides monthly aripiprazole injections. For patients who are stable and want even less frequent dosing, Invega Trinza offers an every-three-months option, Abilify Asimtufii covers every two months, and Invega Hafyera, approved in 2021, requires injection only once every six months. So why does TEV-749 matter if monthly injectables already exist? The answer comes down to the medication itself. Olanzapine consistently ranks among the most effective antipsychotics in head-to-head studies, but the existing options for long-acting injectables are limited to paliperidone and aripiprazole.
Some patients respond far better to olanzapine than to either of those drugs. For those patients, the choice has been daily oral olanzapine with all its adherence challenges, or the three-hour-monitored injection that most clinics find impractical. TEV-749 would fill a genuine gap by making olanzapine available in a convenient long-acting format for the first time. That said, olanzapine is not without tradeoffs. It is well known for causing more weight gain and metabolic side effects than some alternatives. In the SOLARIS trial, 36 percent of participants experienced weight gain, making it the most common side effect by a significant margin. For patients already at risk for diabetes or cardiovascular disease, this is a real consideration, and it does not go away just because the delivery method changes.
Side Effects and Safety Data Families Should Understand
The long-term safety data from the SOLARIS trial, which followed participants through Week 56, paints a reasonably clear picture of what to expect. Seventy-four percent of participants reported at least one treatment-emergent adverse event over the course of the study. That number sounds high, but it is typical for antipsychotic trials of this duration and includes mild events. The most common side effects were weight gain at 36 percent, injection site reactions including induration at 12 percent, pain at 12 percent, redness at 10 percent, and itching at 7 percent, and somnolence or drowsiness at 7 percent. Eight percent of participants discontinued treatment due to adverse events, and 6 percent experienced serious adverse events.
These numbers are within the range that regulators and clinicians generally consider acceptable for an antipsychotic, but they are not trivial. For caregivers, the weight gain figure deserves particular attention. A person with schizophrenia or psychotic symptoms who gains significant weight faces compounding health risks, including diabetes, heart disease, and reduced mobility. If TEV-749 is prescribed, regular metabolic monitoring including blood glucose, cholesterol, and weight checks should be part of the care plan. The injection site reactions, while less medically serious, are worth discussing with the prescribing physician, especially for patients who may have difficulty communicating discomfort.
The Post-Injection Monitoring Problem TEV-749 Could Solve
The existing long-acting olanzapine injection, Zyprexa Relhypv, is a case study in how a safety requirement can effectively kill a useful medication’s adoption. PDSS, or post-injection delirium/sedation syndrome, occurs when olanzapine from the intramuscular depot accidentally enters the bloodstream too rapidly. Symptoms can include severe sedation, delirium, confusion, altered consciousness, and in some cases, cardiovascular instability. The FDA’s Risk Evaluation and Mitigation Strategy, or REMS, for Zyprexa Relhypv requires that every injection be administered in a certified healthcare facility, the patient must be observed for at least three hours afterward by a healthcare professional, and transportation must be arranged because the patient cannot drive themselves home. For a medication given every two to four weeks, this creates an enormous logistical burden. Many outpatient clinics simply do not have the space, staff, or scheduling flexibility to accommodate three-hour observation windows.
The result is that one of the most effective antipsychotics available in long-acting form goes largely unused. TEV-749’s zero-PDSS track record through 56 weeks of follow-up suggests that its subcutaneous delivery and controlled-release technology may genuinely eliminate this risk. If the FDA agrees, the absence of a REMS monitoring requirement would transform olanzapine from a theoretically available long-acting option to a practically usable one. However, it is worth noting that the absence of PDSS in a clinical trial does not guarantee it will never occur in broader real-world use. Clinical trials have controlled conditions and selected populations. Post-marketing surveillance will be important, and clinicians will likely remain watchful during the first few years on the market.
What This Means for Medication Adherence
Medication non-adherence is the single biggest predictor of relapse and hospitalization in schizophrenia. Studies consistently show that roughly half of patients with schizophrenia stop taking their oral medications within a year, often because they feel better and believe they no longer need treatment, because side effects are unpleasant, or because cognitive symptoms make it difficult to maintain a daily routine. Each relapse tends to be harder to recover from than the last, and repeated relapses are associated with progressive functional decline.
Long-acting injectables address this problem directly. A patient who receives a monthly injection at a clinic visit cannot quietly stop taking their medication without their care team knowing. For families who have watched a loved one cycle through periods of stability and crisis, this kind of structured adherence support can be genuinely life-changing. TEV-749 adds olanzapine to the roster of medications available in this format, which means clinicians have another effective tool when paliperidone or aripiprazole injectables are not the right fit.
What Happens Next and When Could TEV-749 Be Available?
The FDA’s acceptance of Teva’s New Drug Application in February 2026 starts a formal review process that typically takes about ten months, though the timeline can vary. If approved, TEV-749 would need to go through the usual steps of insurance formulary negotiations, distribution logistics, and clinician education before it becomes widely available. Realistically, even with an approval later in 2026, broad access may not materialize until 2027 for many patients.
For families and patients watching this space, the key milestones to track are the FDA’s decision date, which Teva will announce as part of the review process, and any advisory committee meetings that the FDA may convene to discuss the application. In the meantime, patients currently stable on oral olanzapine should not change their treatment in anticipation of TEV-749. The best course of action is to continue current treatment and discuss future options with the prescribing psychiatrist once the FDA makes its decision.
Conclusion
TEV-749 represents a meaningful advance in antipsychotic treatment, not because it is a new drug, but because it makes an existing and highly effective drug available in a form that patients and clinicians can actually use without extraordinary logistical hurdles. The elimination of the three-hour post-injection monitoring window, backed by zero PDSS cases through 56 weeks of clinical trial data, is the core breakthrough. Combined with demonstrated efficacy on standard symptom and functioning measures, this injectable has the potential to improve adherence and outcomes for patients who respond best to olanzapine.
Families should approach this development with informed optimism. TEV-749 is not yet approved, and the side effect profile, particularly the 36 percent rate of weight gain, requires honest discussion with healthcare providers. But if the FDA gives it the green light, it will fill a real gap in the treatment landscape. Talk to your loved one’s psychiatrist about whether olanzapine is appropriate for their situation, and ask to be kept informed as the FDA review progresses.
Frequently Asked Questions
Is TEV-749 approved by the FDA?
Not yet. The FDA accepted Teva’s New Drug Application on February 20, 2026, which means the application is under formal review. Acceptance of the NDA is not the same as approval.
Can TEV-749 be used for dementia-related psychosis?
The SOLARIS trial studied adults with schizophrenia, not dementia patients. All antipsychotics carry an FDA black box warning about increased mortality risk in elderly patients with dementia-related psychosis. Any off-label use would need careful physician oversight.
How is TEV-749 different from the existing olanzapine injection (Zyprexa Relhypv)?
Zyprexa Relhypv is an intramuscular injection that carries a risk of post-injection delirium/sedation syndrome and requires three hours of monitoring after every dose. TEV-749 is a subcutaneous injection using different release technology that showed zero cases of PDSS in clinical trials through 56 weeks.
What are the main side effects of TEV-749?
The most common side effects observed in the SOLARIS trial were weight gain (36%), injection site reactions (induration, pain, redness, itching), and drowsiness (7%). Eight percent of participants stopped treatment due to side effects.
Are there other monthly injectable antipsychotics already available?
Yes. Invega Sustenna (paliperidone) and Abilify Maintena (aripiprazole) are both monthly intramuscular injections. Longer-interval options include Invega Trinza (every 3 months), Abilify Asimtufii (every 2 months), and Invega Hafyera (every 6 months). However, none of these contain olanzapine.
Does the patient need to stay at the clinic after receiving TEV-749?
Based on clinical trial data showing zero cases of PDSS, TEV-749 would likely not require post-injection monitoring if approved. This is a significant practical advantage over the existing olanzapine LAI, which requires a three-hour observation period.
